TITLE

CLINIC ROUNDUP

PUB. DATE
November 2009
SOURCE
BioWorld Today;11/18/2009, Vol. 20 Issue 223, p8
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
This section offers news briefs on clinical trials. GlaxoSmithKline PLC, a partner of Anacor Pharmaceuticals Inc., has given six million U.S. dollars to Anacor as a milestone payment for the dosing of the first patient in a Phase I trial of AN3365 for hospital infections caused by Gram-negative bacteria. A pilot study by IntelGenx Corp. of INT008 found that it is bioequivalent to a leading anti-migraine therapy. Pluristem Therapeutics has obtained positive results from a study of its placenta-derived product for critical limb ischemia.
ACCESSION #
46706718

 

Related Articles

  • PLURISTEM GETS INTERIM TOP-LINE RESULTS FROM PLX-PAD TRIALS.  // Worldwide Biotech;Jun2010, Vol. 22 Issue 6, p3 

    The article reports on the interim top-line results from the Phase I clinical trials of Pluristem Therapeutics Inc. in Haifa, Israel, in June 2010, which utilize the placenta-derived cell therapy product PLX-PAD for treating critical limb ischemia (CLI). The interim data showed that PLX-PAD is...

  • Pluristem's Placenta-Derived Cell Therapy Yields Strong Early Data. Boggs, Jennifer // BioWorld Today;4/28/2010, Vol. 21 Issue 81, p1 

    This article reports on the plan of Pluristem Therapeutics Inc. to conduct Phase II testing with its placenta-derived cell therapy treatment PLX-PAD in critical limb ischemia. The Israeli company announced the plan after reporting positive results from two Phase I trials of the treatment,...

  • Pluristem files IND application to begin Phase I critical limb ischemia trial.  // PharmaWatch: Biotechnology;Mar2009, Vol. 8 Issue 3, p10 

    The article reports on the investigational drug application filed by Pluristem Therapeutics to the U.S. Food and Drug Administration (FDA) in its aim to commence clinical trial with its placental-derived stromal cell product for the treatment of critical limb ischemia. The firm will begin its...

  • Clinic Roundup.  // BioWorld Today;6/24/2011, Vol. 22 Issue 122, p7 

    This section offers news briefs concerning clinical trials. 4SC AG's Phase II SHELTER trial of oral resminostat for treatment of hepatocellular carcinoma found that 61 percent of the patients demonstrated tumor stabilization. Anacor Pharmaceuticals Inc. and GlaxoSmithKline plc launched two...

  • Antibiotic Returned to Anacor; Safety Stalls GSK Development. Shaffer, Catherine // BioWorld Today;10/ 8/2012, Vol. 23 Issue 195, p1 

    The article reports on the decision of GlaxoSmithKline PLC to discontinue the development of GSK2251051, a systemic antibiotic. Anacor Pharmaceuticals Inc. has suspended the Phase I/II trials of the compounds, eight months ago, because of the unexpected microbiological findings in patients...

  • Anacor Pharmaceuticals Announces That Its Partner GSK Has Voluntarily Paused Enrollment of Ongoing GSK '052 Phase 1 and 2 Clinical Trials.  // Biomedical Market Newsletter;2/7/2012, Vol. 21, p1 

    The article presents information on the announcement made by Anacor Pharmaceuticals Inc. regarding its partnership with GlaxoSmithKline. It is announced that GlaxoSmithKline voluntarily paused the enrollment in clinical trials of one of its treatment therapy due to microbiological finding in...

  • Migraine Update.  // PharmaWatch: CNS;Aug2010, Vol. 9 Issue 8, p6 

    The article offers updates related to migraine drugs. The British Medicines and Healthcare Products Regulatory Agency has licensed Botox for prophylaxis of headaches in adults with chronic migraine. GlaxoSmithKline and XenoPort Inc. revealed that GSK1838262 did not show significant improvement...

  • Financings Roundup.  // BioWorld Today;2/10/2012, Vol. 23 Issue 19, p6 

    This section reports on Anacor Pharmaceuticals Inc.'s plan to sell 3.25 million shares of common stock at 6.60 per share to raise 21.5 million U.S. dollars, and the decision of GlaxoSmithKline PLC to suspend the enrollment in Phase I and II trials of a systemic antibiotic for Gram-negative...

  • RedHill Biopharma Announces a Successful Pivotal Bioequivalence Trial with RHB- 103 for the Treatment of Migraine.  // Biomedical Market Newsletter;6/1/2012, Vol. 21, p1 

    The article informs that RedHill Biopharma Ltd. has released the results from its clinical trial of rizatriptan for the treatment of acute migraine. It mentions that IntelGenx Corp. has filed a New Drug Application for its marketing in the U.S. It further informs about the other drugs developed...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics